Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
By late June, Cara Therapeutics, Inc. (NASDAQ: CARA) stock had soared more than 175% year to date. Within a couple of weeks, however, many of those gains had been lost. Cara shares crashed after the biotech reported disappointing results from a phase 2 study of experimental pain drug CR845.
While the stock has climbed back somewhat, Cara is still well below the lofty levels of earlier in the summer. Can the comeback continue? I think so. Here's why the best is probably yet to come for Cara Therapeutics.
Image source: Getty Images.
Source: Fool.com
Cara Therapeutics Inc. Aktie
0,25 €
-0,53 %
Die Cara Therapeutics Inc. Aktie ist etwas beliebter: Mehr Buy- (10) als Sell-Einschätzungen (7).
Mit einem Community-Kursziel von 4 € für Cara Therapeutics Inc. wird ein starkes Wachstumspotenzial gegenüber dem aktuellen Kurs von 0.25 € gesehen.
